PARP1 and cancer: Interestingly, the combination of ATR inhibitor with Olaparib synergistically sensitizes NEIL3 deficient cancer cells (Figure 6A-6F), suggesting that blocking the ATR-mediated DNA damage response synergizes the cytotoxicity of PARP1 inhibitor.